Alcon Inc. Q1 2026 Earnings Recap

ALC Q1 2026 May 8, 2026

Get alerts when ALC reports next quarter

Alcon’s shares fell sharply by 14.2% following earnings, primarily reflecting investor disappointment with cautious outlook commentary and uneven market conditions in the cataract segment despite new product introductions.

Earnings Per Share Beat

$0.85 vs $0.80 est.

+6.2% surprise

Revenue Beat

2653435000 vs 2642276000 est.

+0.4% surprise

Market Reaction

1-Day -0.86%

5-Day +1.73%

See ALC alongside your other holdings

Add to your portfolio — free

Key Takeaways

Q1 experienced a mixed performance, with growth driven by new product launches and share gains in U.S. AT-IOLs, surgical equipment, consumables, contact lenses, and dry eye categories.
Cataract market conditions remained uneven, contributing to investor concern.
The Unity platform, including Unity VCS and Unity CS, showed promising momentum with strong surgeon engagement and an expanding installed base.
U.S. share gains in presbyopia-correcting IOLs largely supported by PanOptix Pro, with gradual international rollouts underway.
Early adoption of Valeda for dry AMD shows encouraging clinical potential, but broader market impact remains limited for now.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit ALC on AllInvestView.

Previous Q3 2025